LifeStance Health Group, Inc.
LFSTNasdaqCIK 1845257HealthcareFiscal year ends Dec 31
Reports and events: 77 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-05-1018:11 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-019901 |
| 2023-04-2116:18 ET | DEF 14A | Proxy statementPeriod 2023-06-01 | 0000950170-23-013853 |
| 2023-03-0916:10 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-007018 |
| 2023-03-0818:52 ET | 8-K | 2.02 Results of operations; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-006541 |
| 2022-11-0916:22 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-023899 |
| 2022-11-0816:18 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-22-023246 |
| 2022-11-0316:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-276872 |
| 2022-09-0809:16 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-240642 |
| 2022-08-1016:37 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-016508 |
| 2022-08-0916:19 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-22-016085 |
| 2022-06-0216:16 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-166233 |
| 2022-05-2416:27 ET | 8-K | 8.01 Other events | 0001193125-22-158553 |
| 2022-05-2316:52 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-157550 |
| 2022-05-1116:10 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-009328 |
| 2022-05-0916:19 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-22-008508 |
| 2022-04-2116:39 ET | DEF 14A | Proxy statementPeriod 2022-06-01 | 0001193125-22-113103 |
| 2022-03-1716:21 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-004096 |
| 2022-03-1016:21 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-22-003370 |
| 2021-11-1016:25 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000950170-21-004110 |
| 2021-11-0816:19 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-21-003476 |
| 2021-08-2607:34 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-256918 |
| 2021-08-1220:53 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0000950170-21-001308 |
| 2021-08-1116:20 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-21-001270 |
| 2021-06-1516:31 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-21-191198 |
| 2021-06-0806:07 ET | S-1/A | Registration statement, amended | 0001193125-21-184895 |
| 2021-06-0106:06 ET | S-1/A | Registration statement, amended | 0001193125-21-177685 |
| 2021-05-1716:04 ET | S-1 | Registration statement | 0001193125-21-163638 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 10, 2026, 00:30 ET. Listed shows no prices and gives no investment advice.